MediciNova Reports Results From Interim Analysis Of Phase 2 Trial Of MN-001 In NASH / NAFLD: Showed 'reduces serum triglycerides significantly in NASH and NAFLD patients with hypertriglyceridemia after 8 weeks of treatment'